Australian patients with MS have little or no anxiety about treatment-related risks of COVID-19 and most are willing to continue their disease modifying therapy (DMT), a survey has found. While there have been some potential concerns raised about the use of immunomodulatory therapies and the risk of contracting COVID-19 and its outcomes, these are not ...
No worries: MS patients have few concerns about COVID-19 and DMTs
By Michael Woodhead
20 Oct 2020